VEGFA and Abnormal retinal morphology: In 2020, brolucizumab (Beovu, Novartis Pharma AG), another humanised monoclonal single-chain antibody fragment that targets VEGF-A, was approved for the treatment of nAMD, and is currently undergoing late-phase clinical investigation for other retinal diseases, including PDR (NCT04278417), DMO (NCT04058067), and RVOs (NCT03802630 and NCT03810313).